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For acute myeloid leukemia (AML), identiﬁcation of activating mutations in the FMS-like tyrosine kinase-
3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next gen-
eration sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial
(ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can
lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel
ﬁndings alongside data on treatment directed towards actionable aberrations acquired during the pro-
cess. (Clinical Trial: NCT02014558; registered at: 〈https://clinicaltrials.gov/ct2/show/NCT02014558〉)
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The development of kinase inhibitors for the treatment of
leukemia has revolutionized the care of these patients. Since the
introduction of imatinib for the treatment of chronic myeloid
leukemia, multiple other tyrosine kinase inhibitors (TKIs) have
become available [1]. Additionally, for acute myeloid leukemia
(AML), identiﬁcation of activating mutations in the FMS-like tyr-
osine kinase-3 (FLT3) has led to the development of several FLT3-
inhibitors [2–5]. The article herein reports a unique case of AML
that underwent clonal evolution while on a novel FLT3-inhibitor
clinical trial. Here we show that employing therapeutic interven-
tions with these novel targeted therapies can lead to consequences
secondary to selective pressure and clonal evolution of cancer.
Personalizing therapy in realtime based on changing targets pre-
sents both as challenge and an opportunity. Our work herein
presents clinical and next generation sequencing data at the time
of progression to illustrate these important concepts stemming
from Darwinian evolution [6]. We describe novel ﬁndings along-
side data on treatment directed towards actionable aberrations
acquired during the process.2. Clinical course and management
Our work focuses on a 23-year-old male who presented with
3 months history of fatigue and easy bruising along with a 2 dayLtd. This is an open access article u
ogy, Mayo Clinic, 200 First St.
si).history of fever and chest pain. Initial bloodwork revealed a white
blood count of 22.0109/L with 51% circulating blasts, hemoglo-
bin 7.6 g/dL, and a platelet count of 43109/L. A bone marrow
biopsy conﬁrmed a diagnosis of AML. Initial cytogenetic studies
identiﬁed trisomy 8 in all the twenty metaphases examined. Mu-
tational analysis revealed an internal tandem duplication of the
FLT3 gene (FLT3-ITD).
He received standard induction chemotherapy (7þ3) with cy-
tarabine (ARA-C; 100 mg/m2 for 7 days) and daunorubicin (DNM;
60 mg/m2 for 3 days). His induction chemotherapy was compli-
cated by severe palatine and uvular necrosis of indeterminate
etiology (possible mucormycosis), necessitating aggressive surgi-
cal debridement.
Bone marrow biopsy at day 28 demonstrated persistent disease
with 10% bone marrow blasts (Fig. 1). Due to his complicated
clinical course and the presence of a FLT3-ITD, salvage therapy
with 5-azacitidine (5-AZA) and sorafenib (SFN) was instituted.
With the sorafenib and 5-azacitidine, he achieved morpholo-
gical remission (o5% blasts). His older brother was found to be a
10/10 HLA match. Subsequently, he underwent a reduced inte-
nsity conditioning matched-related donor stem cell transplant
(MRD-HCT) with ﬂudarabine and busulfan (FluBu) conditioning
chemotherapy.
The patient unfortunately had relapse of his leukemia on day
þ67 after his allo-HCT (Fig. 1). Sorafenib was brieﬂy reinitiated
and then he enrolled in a novel FLT3-inhibitor (ASP2215) clinical
trial (NCT02014558) [7]. To potentiate the graft-versus-leukemia
(GVL) effect, he received a cryopreserved donor lymphocyte infu-
sion (DLI) during cycle 4 of ASP2215.
Routine surveillance bone marrow biopsy during the ﬁfth cycle
(28 day cycle) of ASP2215 therapy demonstrated 5% bone marrownder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Clinical course and various treatments received for our patient with FLT3þ/trisomy 8 acute myeloid leukemia (AML). (a) The bone marrow blasts (%) are shown at
different time points alongside the treatments received. (b) Schematic representation of selection pressure leading to development of a new clone of FLT3þ/Trisomy
8 leukemia with the Philadelphia t(9;22) translocation. (c) The FLT3-ITD gene mutated to un-mutated peak height ratio is shown at different time points. Abbreviations: 7þ3
- Induction chemotherapy with an anthracycline and cytarabine (see text for details/doses); SFN – Sorafenib; AZA – 5-Azacitadine; ASP2215 – Novel FLT3 inhibitor
(NCT02014558); FluBu – Conditioning chemotherapy with ﬂudarabine and busulfan; FluMel – Conditioning chemotherapy with Fludarabine and melphalan; MRD-SCT –
Matched related stem cell transplant; MUD – SCT – Matched unrelated stem cell transplant; S-HAM – sequential high dose Ara-C chemotherapy with mitoxantrone.
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analyzed all had trisomy 8. However, initially 5 out of 20 and then
later 20 out of 20 of these metaphases had also acquired the
Philadelphia t(9;22) chromosomal translocation. His bone marrow
aspirate/biopsy was also analyzed through a commercial next
generation sequencing (NGS) assay (FoundationONE Heme) with
results shown in Table 1. Salvage chemotherapy (7þ3) was in-
stituted with cytarabine (ARA-C; 100 mg/m2 for 7 days) and
Idarubicin (IDA; 12 mg/m2 for 3 days) with the addition of dasa-
tinib 100 mg per oral (PO) daily given the emergence of the BCR-
ABL1 clone (the new t(9;22) clone with p210 protein transcript).
He developed pneumonitis, pericarditis and rapid relapse fol-
lowing reinduction chemotherapy which prompted treatment
with sequential-high dose cytarabine (ARA-C 3000 mg/m2 days 1,
2, 8 and 9) and mitoxantrone (10 mg/m2 days 3, 4, 10 and 11) [S-
HAM] salvage chemotherapy to achieve aplasia prior to a secondallogeneic transplant. Given that the patient's clone had both the
FLT3 and the BCR-ABL1 aberrations ponatinib was added since it is
a TKI with dual FLT3 and BCR-ABL1 inhibitory activity (Table 1).
This was given at the standard dose of 45 mg PO daily for a week
prior to chemotherapy and at a reduced dose of 15 mg daily during
cytotoxic chemotherapy.
Subsequent bone marrow biopsy prior to the second transplant
did not show any morphological or molecular evidence of leuke-
mia. Patient, therefore, underwent conditioning chemotherapy
with ﬂudarabine and melphalan (FluMel) prior to a matched un-
related donor allogeneic transplant (MUD-SCT) (Fig. 1). This was
complicated by pancreatitis requiring total parenteral nutrition
and supportive care for several weeks. Following this, patient now
has been transitioned to an outpatient setting with excellent signs
of engraftment and is transfusion independent. Day 30, day 60 and
now the 6 month chimerism studies show 100% donor and 0%
Table 1
Commercial next-generation sequencing (NGS) based assay (FoundationONE
Heme) identifying multiple genomic alterations alongside a brief description of
potential personalized targeted therapies. The highlighted therapies were em-
ployed in this particular case at various time points as shown in Fig. 1.
Genomic alterations
detected*
Potential targeted therapy
BCR-ABL1 fusion (p210) Tyrosine kinase inhibitors (TKIs) such as imatinib,
dasatinib, ponatinib, bosutinib, nilotinib and TKIs
available through clinical trials
FLT3-ITD
(E596_Y597ins16)
Tyrosine kinase inhibitors including FLT3 in-
hibitors such as sorafenib, ponatinib, sunitinib,
crenolanib, quizartinib and FLT3 inhibitors avail-
able through clinical trials (e.g. ASP2215, E6201)
GATA2 (F265fs*15) –
MLL2 (R2635Q) Targeting DOT1L (a histone methyltransferase)
WT1 (R380fs*5, R462Q) Potential for using DNA methyltransferase (DNMT)
inhibitors such as azacitidine and decitabine
* Other variants of unknown signiﬁcance that were also detected on NGS assay
included LRP1B(N4559S), MSH3(A62_P63insAAAPAA) and ROS1(Q291P)
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cerns for high risk for relapse, patient was started on ‘main-
tenance’ ponatinib 15 mg every other day and continues to be on
it8 months post-SCT. The molecular mRNA BCR-ABL1 testing
done continue to show no detectable transcripts in the both the
patient's blood and bone marrow.3. Discussion
In this era of novel targeted therapies and personalized cancer
medicine, clonal evolution and tumor heterogeneity are important
concepts stemming from Darwinian evolution [6]. Our work here
illustrates several unique aspects. First we report novel acquisition
of the Philadelphia t(9;22) translocation (p210 isotype) while re-
ceiving FLT3 inhibitor therapy on a clinical trial with ASP2215. This
has not been described previously. There have been cases of AML
with emergence of the BCR-ABL1 clone at the time of relapse, but
not while receiving FLT3 inhibitor targeted therapy [8,9].
Second is the challenging aspect of personalizing cancer
treatment in the light of evolving therapeutic targets. In this pa-
tient's case, there were several potential treatment options to
consider as targeted therapy alone or in combination with cyto-
toxic therapy. For instance, ponatinib is considered both a strong
FLT3-inhibitor as well as a pan-BCR-ABL1 inhibitor for Philadelphia
chromosome positive leukemia. Its ability to act at both these
targets alongside other possible promiscuous interactions, likely
helped achieve a deep morphological and molecular response
when combined with cytotoxic chemotherapy. Dasatinib has also
been shown in cell lines to have FLT3-inhibitor activity but its ef-
ﬁcacy in vivo is not known [10]. Choice of the particular targeted
therapies was further dictated by what insurance companies
would approve of and raises an interesting but challenging issue of
coverage of these costly therapies. Furthermore, the signiﬁcant
improvement in performance status while on ASP2215 clinical trial
allowed us to consider a second allogeneic transplant.
We interpreted the relapse post-SCT in this patient as clonal
evolution. Of note, we did check the initial bone marrow samples
with sensitive qualitative and quantitative methods and did not
detect the presence of t(9;22) clone. This would make the clonal
evolution a more plausible explanation.
The contribution of using a comprehensive method such asnext generation sequencing varies from case to case. One may
argue that conventional cytogenetics and targeted gene testing
may not pick up new or uncommon variants that may be re-
sponsible for acquisition of resistance. With these techniques be-
coming more sensitive and cost-effective, they are likely to be
helpful in refractory/relapse cases as the number of targeted
therapies also continue to increase. Outcomes of patients in this
evolving era of precision-based medicine are likely better as
compared to historical cases due to more novel treatment options.
Ongoing clinical trials to evaluate the safety and efﬁcacy of novel
therapies like ASP2215 in combination with induction and/or
consolidation therapies will help quantify their true beneﬁt in
ﬁrst-line and relapse setting. Testing for targetable drivers of on-
cogenesis and progression can help personalize cancer treatment
and increase treatment options for some of these patients.Conﬂicts of interest disclosures
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